Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Conditions
Keywords
psychosis, psychiatry, complement immune system
Brief summary
The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.
Detailed description
Genetic studies have linked the number of copies coding for C4 protein to risk for schizophrenia. Studies examining the amount of mRNA, the molecules that point to how much C4 protein is likely being made, found more C4 mRNA in the brains from individuals with schizophrenia. Studies in mice have suggested that expressing more C4 protein in the brain, specifically the A-type of C4, can result in abnormalities in behavior. However, researchers have also found that pathways that involve this protein in the blood to be abnormal in individuals even before they develop schizophrenia and hypothesize these abnormalities change the blood brain barrier. In this work, the researchers are hoping to understand the ways in which C4 protein is abnormal in the peripheral blood and how this may be contributing to the disease process in hopes of finding new ways of helping individuals with schizophrenia and possibly other mental health disorders. A major goal of this study is to collect blood tissue for ongoing translational study of pathophysiological mechanisms of schizophrenia. Interested participants will be asked a series of questions about their medical and mental health history, be able to provide informed consent, undergo a urine toxicology screen and be willing to provide a blood sample.
Interventions
DIAGNOSTIC_TESTSCID (Standardized Clinical Interview for DSM-V)
The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
DIAGNOSTIC_TESTPSS (Perceived Stress Score)
The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
DIAGNOSTIC_TESTUrine Toxicology Screen
Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
DIAGNOSTIC_TESTVitals
Height and weight will be measured in order to calculate BMI.
DIAGNOSTIC_TESTBlood Work
A venipuncture will be performed for the purpose of collecting blood tissue for study.
DIAGNOSTIC_TESTPQ-B
The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
DIAGNOSTIC_TESTCOVID Screening
Questionnaire to assess risk of transmission of COVID-19.
DIAGNOSTIC_TESTPositive and Negative Syndrome Scale (PANSS)
Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
Sponsors
Stanford University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
for Subjects with schizophrenia and schizoaffective disorders: * Schizophrenia or schizoaffective disorder diagnosis verified by interview * Diagnosis or initiation of antipsychotic medication was within last 5 years Inclusion Criteria for Healthy Controls: * No known diagnosis of schizophrenia or schizoaffective disorder * No history of depression, anxiety, bipolar disorder, PTSD, agoraphobia, panic disorder, or generalized anxiety disorder * Negative assessment for psychotic symptoms on day of interview
Exclusion criteria
(for both groups): * Participants have a history of bleeding disorders or are taking blood thinners. * Participants have a history of epilepsy, known genetic disorders * Immunocompromised state (eg., receiving immunosuppressive therapy, transplant). * History of brain-related disease (eg., stroke) * Any uncontrolled medical disorder such as cancer. * History of substance abuse or positive urine toxicology screen (including test for marijuana) on the day of the blood draw
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Group comparison of C4 protein in immune cells | Day 1 | Measure the concentration of complement 4 protein in immune cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body Mass Index and its relationship to C4 protein concentration | Day 1 | The relationship between body mass index, calculated from the measured height and weight of participants, and the primary outcome (C4 protein concentration) will be determined. |
| C4 Gene Copy Number | Day 1 | Determine the C4 Gene Copy Number its relationship to C4 protein concentration in immune cells. |
| C4 Activation | Day 1 | Measure activity of C4 protein and its relationship to the primary outcome. |
| Relationship to symptom presentation | Day 1 | Explore the relationship between clinical severity scores (PANSS) and the primary outcome. |
| Relationship to stress | Day 1 | Explore the relationship between perceived stress (PSS) and the primary outcome. |
Countries
United States
Outcome results
None listed